<DOC>
	<DOCNO>NCT00454753</DOCNO>
	<brief_summary>This protocol allow CML Ph+ ALL subject resistant intolerant imatinib mesylate , potentially benefit dasatinib . It intend provide patient access dasatinib await reimbursement decision Korea also provide additional data safety dasatinib Korean population</brief_summary>
	<brief_title>Korean Early Access Program</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Clinical diagnosis CML Ph+ ALL primary acquire resistance intolerance imatinib mesylate ECOG performance status score 0 2 Adequate hepatic , renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Myeloid , Chronic</keyword>
	<keyword>Lymphocytic , Acute</keyword>
</DOC>